News >

Expert Addresses Optimal Use of Endocrine Therapy in HR+ Breast Cancer

Caroline Seymour
Published: Wednesday, May 09, 2018

Rena D. Callahan, MD

Rena D. Callahan, MD
Results of a meta-analysis revealed that the use of endocrine therapy for 5 years significantly reduced recurrence rates in women with early-stage, estrogen receptor (ER)-positive breast cancer with additive benefits that extend beyond 5 years. However, the apparent benefit, notes Rena D. Callahan, MD, must be weighed against adverse events (AEs).

on Breast Cancer, Callahan, an assistant clinical professor of medicine at the University of California, Los Angeles Jonsson Comprehensive Cancer Center, discussed controversies in the management of early-stage HR-positive breast cancer and neoadjuvant trial designs for these patients.

OncLive: Please provide an overview of your presentation.

Callahan: It was my pleasure to discuss the optimal duration of endocrine therapy, because this is a hot topic that affects a lot of our patients. Most of our patients have early-stage and ER-positive disease, so this is very relevant to them. Over the past several years, we’ve been toying with the idea of whether or not we can get more of a good thing. Physicians know that more aggressive cancers, such as triple-negative breast cancer or ER-negative, HER2-positive breast cancer, tend to recur early. A patient with those tumor types who reaches 5 years can feel confident that they will not have disease recurrence. It is very different for ER-positive disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication